{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:50:25Z","timestamp":1791406225504,"version":"4.3.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T00:00:00Z","timestamp":1556323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s40265-019-01120-1","type":"journal-article","created":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T07:45:13Z","timestamp":1556351113000},"page":"767-777","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":127,"title":["Pegaspargase: A Review in Acute Lymphoblastic Leukaemia"],"prefix":"10.1007","volume":"79","author":[{"given":"Young-A.","family":"Heo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahiya Y.","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan J.","family":"Keam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,27]]},"reference":[{"key":"1120_CR1","unstructured":"National Comprehensive Cancer Network. Acute lymphoblastic leukemia (NCCN clinical practice guidelines in oncology). 2018. \n                    http:\/\/www.nccn.org\/\n                    \n                  . Accessed 4 Mar 2019."},{"issue":"Suppl 5","key":"1120_CR2","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/annonc\/mdw025","volume":"27","author":"D Hoelzer","year":"2016","unstructured":"Hoelzer D, Bassan R, Dombret H, et al. Acute lymphoblastic leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(Suppl 5):v69\u201382.","journal-title":"Ann Oncol"},{"key":"1120_CR3","first-page":"621","volume-title":"Drug resistance in leukemia and lymphoma III Advances in experimental medicine and biology","author":"BL Asselin","year":"1999","unstructured":"Asselin BL. The three asparaginases: comparative pharmacology and optimal use in childhood leukemia. In: Kaspers GJL, Pieters R, Veerman AJP, editors. Drug resistance in leukemia and lymphoma III Advances in experimental medicine and biology. Boston: Springer; 1999. p. 621\u20139."},{"issue":"2","key":"1120_CR4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1056\/NEJMra052603","volume":"354","author":"CH Pui","year":"2006","unstructured":"Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166\u201378.","journal-title":"N Engl J Med"},{"issue":"7","key":"1120_CR5","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1182\/blood-2009-09-245951","volume":"115","author":"LB Silverman","year":"2010","unstructured":"Silverman LB, Supko JG, Stevenson KE, et al. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood. 2010;115(7):1351\u20133.","journal-title":"Blood"},{"issue":"13","key":"1120_CR6","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1182\/blood-2013-10-534347","volume":"123","author":"WH Tong","year":"2014","unstructured":"Tong WH, Pieters R, Kaspers GJ, et al. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood. 2014;123(13):2026\u201333.","journal-title":"Blood"},{"issue":"6","key":"1120_CR7","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1002\/jps.22054","volume":"99","author":"DS Pisal","year":"2010","unstructured":"Pisal DS, Kosloski MP, Balu-Iyer SV. Delivery of therapeutic proteins. J Pharm Sci. 2010;99(6):2557\u201375.","journal-title":"J Pharm Sci"},{"key":"1120_CR8","unstructured":"Shire Pharmaceuticals. Oncaspar (pegaspargase): US prescribing information. 2019. \n                    http:\/\/www.fda.gov\n                    \n                  . Accessed 9 Apr 2019."},{"key":"1120_CR9","unstructured":"European Medicines Agency. Oncaspar (pegaspargase): summary of product characteristics. 2018. \n                    http:\/\/www.ema.europa.eu\/\n                    \n                  . Accessed 9 Apr 2019."},{"key":"1120_CR10","unstructured":"Servier Pharmaceuticals. ASPARLAS\u2122 (calaspargase pegol\u2014mknl): US prescribing information. 2018. \n                    http:\/\/www.fda.gov\n                    \n                  . Accessed 9 Apr 2019."},{"issue":"6","key":"1120_CR11","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","volume":"99","author":"VI Avramis","year":"2002","unstructured":"Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a children\u2019s cancer group study. Blood. 2002;99(6):1986\u201394.","journal-title":"Blood"},{"issue":"16","key":"1120_CR12","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S1470-2045(15)00363-0","volume":"16","author":"AE Place","year":"2015","unstructured":"Place AE, Stevenson KE, Vrooman LM, et al. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015;16(16):1677\u201390.","journal-title":"Lancet Oncol."},{"key":"1120_CR13","unstructured":"European Medicines Agency. EPAR assessment report: oncaspar 2016. \n                    http:\/\/www.ema.europa.eu\n                    \n                  . Accessed 9 Apr 2019."},{"issue":"6","key":"1120_CR14","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s13318-017-0410-5","volume":"42","author":"G Wurthwein","year":"2017","unstructured":"Wurthwein G, Lanvers-Kaminsky C, Hempel G, et al. Population pharmacokinetics to model the time-varying clearance of the pegylated asparaginase Oncaspar(R) in children with acute lymphoblastic leukemia. Eur J Drug Metab Pharmacokinet. 2017;42(6):955\u201363.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"34","key":"1120_CR15","doi-asserted-by":"publisher","first-page":"3874","DOI":"10.1200\/JCO.2014.55.5763","volume":"32","author":"AL Angiolillo","year":"2014","unstructured":"Angiolillo AL, Schore RJ, Devidas M, et al. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli l-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from children\u2019s oncology group study AALL07P4. J Clin Oncol. 2014;32(34):3874\u201382.","journal-title":"J Clin Oncol"},{"issue":"23","key":"1120_CR16","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1182\/blood.V126.23.80.80","volume":"126","author":"DJ DeAngelo","year":"2015","unstructured":"DeAngelo DJ, Stevenson K, Neuberg DS, et al. A multicenter phase II study using a dose intensified pegylated-asparaginase pediatric regimen in adults with untreated acute lymphoblastic leukemia: a DFCI ALL consortium trial [abstract]. Blood. 2015;126(23):80.","journal-title":"Blood"},{"issue":"8","key":"1120_CR17","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1634\/theoncologist.12-8-991","volume":"12","author":"PA Dinndorf","year":"2007","unstructured":"Dinndorf PA, Gootenberg J, Cohen MH, et al. FDA drug approval summary: pegaspargase (Oncaspar\u00ae) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist. 2007;12(8):991\u20138.","journal-title":"Oncologist."},{"issue":"9","key":"1120_CR18","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1200\/JCO.2013.50.2708","volume":"32","author":"D Douer","year":"2014","unstructured":"Douer D, Aldoss I, Lunning MA, et al. Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia. J Clin Oncol. 2014;32(9):905\u201311.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1120_CR19","first-page":"75","volume":"15","author":"J Liang","year":"2018","unstructured":"Liang J, Shi P, Guo X, et al. A retrospective comparison of Escherichia coli and polyethylene glycol-conjugated asparaginase for the treatment of adolescents and adults with newly diagnosed acute lymphoblastic leukemia. Oncol Lett. 2018;15(1):75\u201382.","journal-title":"Oncol Lett."},{"issue":"21","key":"1120_CR20","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.V122.21.839.839","volume":"122","author":"N G\u00f6kbuget","year":"2013","unstructured":"G\u00f6kbuget N, Beck J, Brandt K, et al. Significant improvement of outcome in adolescents and young adults (AYAs) aged 15-35\u00a0years with acute lymphoblastic leukemia (ALL) with a pediatric derived adult ALL protocol; results of 1529 AYAs in 2 consecutive trials of the german multicenter study group for adult ALL (GMALL) [abstract]. Blood. 2013;122(21):839.","journal-title":"Blood"},{"issue":"8","key":"1120_CR21","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/ajh.24419","volume":"91","author":"ME Rytting","year":"2016","unstructured":"Rytting ME, Jabbour EJ, Jorgensen JL, et al. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Munster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol. 2016;91(8):819\u201323.","journal-title":"Am J Hematol"},{"issue":"7","key":"1120_CR22","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1080\/10428194.2017.1397661","volume":"59","author":"JM Ribera","year":"2018","unstructured":"Ribera JM, Morgades M, Montesinos P, et al. Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, philadelphia chromosome-negative acute lymphoblastic leukemia. Leuk Lymphoma. 2018;59(7):1634\u201343.","journal-title":"Leuk Lymphoma"},{"issue":"14","key":"1120_CR23","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","volume":"133","author":"W Stock","year":"2019","unstructured":"Stock W, Luger SM, Advani AS, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019;133(14):1548\u201359.","journal-title":"Blood."},{"issue":"10","key":"1120_CR24","doi-asserted-by":"publisher","first-page":"4164","DOI":"10.1182\/blood-2006-09-045351","volume":"109","author":"M Wetzler","year":"2007","unstructured":"Wetzler M, Sanford BL, Kurtzberg J, et al. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: cancer and leukemia group B Study 9511. Blood. 2007;109(10):4164\u20137.","journal-title":"Blood"},{"key":"1120_CR25","unstructured":"Therapeutic Goods Administration. Extract from the clinical evaluation report for pegaspargase. 2017. \n                    http:\/\/www.tga.gov.au\/\n                    \n                  . Accessed 9 Apr 2019."},{"issue":"8","key":"1120_CR26","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1097\/MPH.0b013e31822d4d4e","volume":"33","author":"J Kurtzberg","year":"2011","unstructured":"Kurtzberg J, Asselin B, Bernstein M, et al. Polyethylene glycol-conjugated l-asparaginase versus native l-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a children\u2019s oncology group study (POG 8866). J Pediatr Hematol Oncol. 2011;33(8):610\u20136.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"12","key":"1120_CR27","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.3109\/10428194.2011.596963","volume":"52","author":"W Stock","year":"2011","unstructured":"Stock W, Douer D, DeAngelo DJ, et al. Prevention and management of asparaginase\/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011;52(12):2237\u201353.","journal-title":"Leuk Lymphoma"},{"key":"1120_CR28","unstructured":"De Abrew KG, Richardson DS, Cook MA, et al. Hepatotoxicity with pegylated-asparaginase in acute lymphoblastic leukaemia is influenced by raised body mass index [abstract no. 249]. Br J Haematol. 2016;173 (Suppl 1):103."},{"issue":"1","key":"1120_CR29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/pbc.26200","volume":"64","author":"H Hasan","year":"2017","unstructured":"Hasan H, Shaikh OM, Rassekh SR, et al. Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: a meta-analysis and systematic review. Pediatr Blood Cancer. 2017;64(1):81\u20138.","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"1120_CR30","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/MPH.0000000000000520","volume":"38","author":"T MacDonald","year":"2016","unstructured":"MacDonald T, Kulkarni K, Bernstein M, et al. Allergic reactions with intravenous compared with intramuscular pegaspargase in children with high-risk acute lymphoblastic leukemia: a population-based study from the maritimes, Canada. J Pediatr Hematol Oncol. 2016;38(5):341\u20134.","journal-title":"J Pediatr Hematol Oncol."},{"issue":"4","key":"1120_CR31","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40272-015-0129-1","volume":"17","author":"LS Abbott","year":"2015","unstructured":"Abbott LS, Zakova M, Shaikh F, et al. Allergic reactions associated with intravenous versus intramuscular pegaspargase: a retrospective chart review. Paediatr Drugs. 2015;17(4):315\u201321.","journal-title":"Paediatr Drugs"},{"key":"1120_CR32","doi-asserted-by":"crossref","unstructured":"Burke MJ, Devidas M, Maloney K, et al. Severe pegaspargase hypersensitivity reaction rates (grade\u2009\u2265 3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children\u2019s oncology group (COG) clinical trials. Leuk Lymphoma. 2018;59(7):1624\u201333.","DOI":"10.1080\/10428194.2017.1397658"},{"key":"1120_CR33","unstructured":"National Institue for Health and Care Excellence. Technology appraisal guidance: pegaspargase for treating acute lymphoblastic leukaemia. 2016. \n                    http:\/\/www.nice.org.uk\n                    \n                  . Accessed 9 Apr 2019."},{"issue":"3","key":"1120_CR34","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3324\/haematol.2015.137380","volume":"101","author":"IM Sluis van der","year":"2016","unstructured":"van der Sluis IM, Vrooman LM, Pieters R, et al. Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. Haematologica. 2016;101(3):279\u201385.","journal-title":"Haematologica"},{"key":"1120_CR35","doi-asserted-by":"crossref","unstructured":"Basu S, Lin PL, Saha V. The cost-effectiveness of pegaspargase for first-line treatment of acute lymphoblastic leukaemia: a cost-utility analysis. [abstract no. PCN180]. Value Health. 2017;20 (9):A444.","DOI":"10.1016\/j.jval.2017.08.263"},{"key":"1120_CR36","doi-asserted-by":"crossref","unstructured":"Delattre C, Lecureuil C, Staginnus U, et al. Cost-minimization analysis of pegaspargase and native E. Coli asparaginase to treat children and adults with acute lymphoblastic leukemia in Belgium. [abstract no. PSY86]. Value Health. 2016;19(7):A590.","DOI":"10.1016\/j.jval.2016.09.1401"},{"key":"1120_CR37","doi-asserted-by":"crossref","unstructured":"Faiella M, Lecureuil C, Staginnus U, et al. Pegaspargase in the treatment of Acute Lymphoblastic Leukemia: A CMA model demonstrates its economic benefit for the Italian National Health System. [abstract no. PSY87]. Value Health. 2016;19 (7):A590.","DOI":"10.1016\/j.jval.2016.09.1402"},{"key":"1120_CR38","doi-asserted-by":"crossref","unstructured":"Lecureuil C, Staginnus U, Robbins S, et al. Pegaspargase versus asparaginase in childhood acutely lymphoblastic leukemia: a cost-minimization analysis in France. [abstract no. PSY84]. Value Health. 2016;19(7):A589\u2013A90.","DOI":"10.1016\/j.jval.2016.09.1399"},{"key":"1120_CR39","doi-asserted-by":"crossref","unstructured":"Villoro R, Aisa F, Domenech M, et al. Pharmacoeconomic assessment of pegaspargase versus asparaginase in acute lymphocytic leukemia. [abstract no. PCN169]. Value Health. 2016;19 (7):A739.","DOI":"10.1016\/j.jval.2016.09.2243"},{"key":"1120_CR40","unstructured":"US National Institutes of Health. ClinicalTrials.gov [identifier NCT01574274]. 2018.\n                    http:\/\/www.clinicaltrials.gov\/\n                    \n                  . Accessed 9 Apr 2019."},{"key":"1120_CR41","unstructured":"US National Institutes of Health. ClinicalTrials.gov [identifier NCT00671034]. 2018.\n                    http:\/\/www.clinicaltrials.gov\/\n                    \n                  . Accessed 9 Apr 2019."}],"updated-by":[{"DOI":"10.1007\/s40265-019-01137-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T00:00:00Z","timestamp":1558051200000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01120-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-019-01120-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01120-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T23:10:41Z","timestamp":1587856241000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-019-01120-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,27]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["1120"],"URL":"https:\/\/doi.org\/10.1007\/s40265-019-01120-1","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40265-019-01137-6","asserted-by":"object"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,27]]},"assertion":[{"value":"27 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2019","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been corrected.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Young-A Heo, Yahiya Syed and Susan Keam are salaried employees of Adis\/Springer, are responsible for the article content and declare no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}